SINGAPORE (June 5): Maybank Kim Eng Research continues to rate Raffles Medical Group (RMG) at “buy” as Singapore’s leading integrated healthcare provider, with a “robust track record and exciting development plans” of two hospitals in China.

In a Monday report, analyst John Cheong says he finds the shares of RMG undervalued as it is trading at 32 times FY17 P/E – with its current stock price largely reflecting solely the Singapore operations, without fully accounting for its new hospitals in China.

The research house’s price target estimate, however, has been lowered to $1.54 from $1.67 previously after accounting for greater expansion risks in China given higher execution risks for its Shanghai and Chongqing hospitals, both firsts for the group outside of Singapore; higher-than-expected start-up costs in major expansion markets; and the potential of a continued structural decline of medical tourism Singapore.

Regardless of these risks, Cheong maintains that RMG’s Singapore market, which still contributes to the majority of the group’s earnings, should remain stable.

He also believes the current weakness from medical tourism could be temporary, as patients who are deferring treatments due to a weak economy could possibly return.

Additionally, demand from local patients could improve as Singapore’s economy recovers, says Cheong.

“For [RMG’s] China expansion, both Shanghai and Chongqing Hospitals could lift growth in the mid to long term. We expect both hospitals to turn profitable in 2020, the second full year of operation. However, we caution that start-up costs in 2018 and initial operating losses in 2019 will drag earnings,” observes the analyst.

As at 1:36pm, shares of RMG are trading 0.4% higher at $1.37.

Medical tourism weakness in Singapore could be temporary: Maybank 

Singapore 'acutely aware' of global competition to be AI hub, plans to triple AI talent pool to 15,000

MSCI boss warns of climate risks

Keppel to acquire 50% stake in European asset manager Aermont Capital for up to $517 mil

Local banks 'resilient' in 2023, but MAS warns of deteriorating asset quality, climate transition risks

The new kings and queens of content

UOB Kay Hian and CGS-CIMB analysts stay put on IHH Healthcare

CGS-CIMB reiterates Boustead Singapore at 'add' and $1.40

Citi lowers FLCT's TP to $1.24, cuts FY2024 and FY2025 DPU estimates by 8.4%

Medical tourism weakness in Singapore could be temporary: Maybank

Related News

Highlights

Singapore 'acutely aware' of global competition to be AI hub, plans to triple AI talent pool to 15,000

Related News

UOB Kay Hian lowers MPACT’s TP, DPU on lower contributions from China and further depreciation on forex

OCBC remains RHB’s top pick after 3QFY2023 results

Jack Ma urges Alibaba to ‘correct course’ in internal memo